Insys Therapeutics Inc (INSY) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Summary

Insys Therapeutics Inc (Insys) is a specialty pharmaceutical company, which discovers, develops and commercializes novel drug delivery systems of therapeutic compounds. The company harnesses its proprietary sublingual spray technology to develop pharmaceutical cannabinoids. Its flagship product, Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP). Its lead product candidate, Syndros (dronabinol oral solution), is intended for the treatment of chemotherapy-induced nausea and vomiting (CINV) and anorexia associated with weight loss in AIDS patients. The company offers its products to oncologists, pain specialists and supportive care centers for the potential treatment of addiction to opioids, opioid overdose and epilepsy. It has operations in the US and offers its products in international markets. Insys is headquartered in Chandler, Arizona, the US.

Insys Therapeutics Inc (INSY) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 5
List of Figures 5
Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Insys Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
INSYS Therapeutics Enters into Agreement with University of California San Diego 11
Licensing Agreements 12
Lunatus to Enter into Licensing Agreement with Insys Therapeutics 12
Insys Therapeutics Enters into Licensing Agreement with Senzer 13
Insys Therapeutics Enters into Licensing Agreement with Gold Coast Therapeutics 14
Insys Therapeutics Enters into Licensing Agreement with California Pacific Medical Center Research Institute 15
Equity Offering 16
Insys Therapeutics Completes IPO For US$36.8 Million 16
Insys Therapeutics Inc - Key Competitors 18
Insys Therapeutics Inc - Key Employees 19
Insys Therapeutics Inc - Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Recent Developments 21
Financial Announcements 21
May 08, 2018: INSYS Therapeutics Reports First Quarter 2018 Results 21
Mar 08, 2018: INSYS Therapeutics Reports Fourth Quarter and Full Year 2017 Results 23
Nov 02, 2017: INSYS Therapeutics Reports Third Quarter 2017 Results 24
Aug 03, 2017: Insys Therapeutics Reports Second Quarter 2017 Results 25
May 09, 2017: Insys Therapeutics Reports First Quarter 2017 Results 26
Apr 03, 2017: Insys Therapeutics Reports Fourth Quarter and Year End 2016 Results 27
Corporate Communications 29
Apr 02, 2018: INSYS Therapeutics Appoints Trudy Vanhove to Board of Directors 29
Feb 01, 2018: INSYS Therapeutics Appoints Vaseem Mahboob to Board of Directors 30
Oct 29, 2017: INSYS Therapeutics Announces Resignation of Patrick P. Fourteau from Board of Directors 31
Oct 29, 2017: INSYS Therapeutics Founder Dr. John N. Kapoor Steps Down from Board of Directors 32
Jul 18, 2017: Insys Therapeutics Appoints Andrew G. Long as Chief Financial Officer 33
May 16, 2017: Insys Therapeutics Announces Chief Financial Officer Transition 34
May 04, 2017: Insys Therapeutics Appoints Rohit Vishnoi to Board of Directors 35
Apr 24, 2017: Dr. Steven James Joins Insys Therapeutics as Vice President of Medical Affairs 36
Mar 27, 2017: Insys Announces Saeed Motahari to Become President and Chief Executive Officer and Member of the Board of Directors Effective April 17, 2017 37
Jan 09, 2017: Insys Therapeutics Announces Retirement of Dr. John N. Kapoor as CEO and Chairman; Appoints Dr. Santosh Vetticaden as Interim CEO and Steven Meyer as Chairman of the Board 38
Legal and Regulatory 39
May 15, 2018: INSYS Therapeutics Responds to Unsealing of Previously Filed Qui Tam Complaints and Recaps Transformation Efforts 39
Oct 29, 2017: INSYS Therapeutics to Record a Minimum Liability for Department of Justice Settlement in Q3 2017 40
Product News 41
07/31/2017: Insys Announces Availability of SYNDROS, the First and Only FDA-Approved Liquid Dronabinol, by Prescription 41
05/24/2017: Insys Therapeutics Announces FDA Final Product Label for Syndros 42
Product Approvals 43
Dec 06, 2017: FDA Accepts New Drug Application (NDA) for Buprenorphine Sublingual Spray from INSYS Therapeutics 43
Sep 29, 2017: INSYS Therapeutics Files New Drug Application (NDA) for Buprenorphine Sublingual Spray with FDA 44
Mar 23, 2017: DEA Schedules Insys Therapeutics Syndros (dronabinol oral solution) as Schedule II Drug 45
Clinical Trials 46
Dec 07, 2017: INSYS Therapeutics Starts Proof-of-Concept Study of Epinephrine Nasal Spray for Anaphylaxis 46
Other Significant Developments 47
Jun 18, 2018: INSYS Therapeutics Provides an Update on Its Ongoing Transformation 47
Feb 09, 2018: INSYS Therapeutics Addresses Maryland Attorney Generals Motion 48
Appendix 49
Methodology 49
About GlobalData 49
Contact Us 49
Disclaimer 49

List Of Tables

List of Tables
Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Insys Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Insys Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
INSYS Therapeutics Enters into Agreement with University of California San Diego 11
Lunatus to Enter into Licensing Agreement with Insys Therapeutics 12
Insys Therapeutics Enters into Licensing Agreement with Senzer 13
Insys Therapeutics Enters into Licensing Agreement with Gold Coast Therapeutics 14
Insys Therapeutics Enters into Licensing Agreement with California Pacific Medical Center Research Institute 15
Insys Therapeutics Completes IPO For US$36.8 Million 16
Insys Therapeutics Inc, Key Competitors 18
Insys Therapeutics Inc, Key Employees 19
Insys Therapeutics Inc, Other Locations 20
Insys Therapeutics Inc, Subsidiaries 20

List Of Figures

List of Figures
Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Insys Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Insys Therapeutics Inc (INSY) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Insys Therapeutics Inc (Insys) is a specialty pharmaceutical company, which discovers, develops and commercializes novel drug delivery systems of therapeutic compounds. The company harnesses its proprietary sublingual spray technology to

USD 250 View Report

Insys Therapeutics Inc Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Insys Therapeutics Inc Company Profile is a detailed strategic and analytical report on Insys Therapeutics Inc. The 2018 version of the report offers detailed insights into the companys strategies, developments,

USD 200 View Report

Nuo Therapeutics Inc (AURX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Nuo Therapeutics Inc (Nuo Therapeutics), formerly Cytomedix, is a biomedical company that specializes in biodynamic therapies in the area of wound care. It focuses on commercializing cell-based technologies, which bind

USD 250 View Report

Assertio Therapeutics Inc (DEPO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Assertio Therapeutics Inc (Assertio), formerly Depomed Inc, is a specialty pharmaceutical company that develops and commercializes drugs for the treatment of pain and other diseases of the central nervous system.

USD 250 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available